MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PNU-159682

CAS No. : 202350-68-3

MCE 国际站：PNU-159682

产品活性：PNU-159682 是蒽环类新霉素代谢产物的代谢产物，是一种 DNA 拓扑异构酶 I (Topo I) 抑制剂，具有出色的细胞毒性。在ADC 合成中，PNU-159682 是一种比阿霉素更有效和耐受性更高的 ADC 细胞毒素 (ADC cytotoxin)。PNU-159682 可用于 EDV 纳米细胞技术，克服耐药性。

研究领域：Antibody-drug Conjugate/ADC Related | Cell Cycle/DNA Damage

作用靶点：ADC Cytotoxin | Topoisomerase

In Vitro: PNU-159682 (0-500 nM; exposed to the compounds for 1 hour and then cultured in compound-free medium for 72 hours) has cytotoxic effects on human tumor cell lines in a sulforhodamine B assay. The IC₇₀ values are 0.577 nM, 0.39 nM, 0.128 nM, and 0.081 nM, 0.086 nM and 0.075 nM for HT-29, A2780, DU145, EM-2, Jurkat and CEM cells, respectively. It against human tumor cell lines with IC₇₀ in the ranging 68 nM-578 nM and 181 nM-1717 nM towards MMDX and doxorubicin, respectively.
PNU-159682 is more potent than MMAE on NHL cell lines. In a cell viability assay, PNU-159682 is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC₅₀ values of 0.10 nM, 0.020 nM, 0.055 nM, and 0.1 nM, respectively. While MMAE is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC₅₀ values of 0.54 nM, 0.25 nM, 1.19 nM and 0.25 nM, respectively.
PNU-159682 is thousands of times more cytotoxic than doxorubicin and can be used to develop a new class of ADCs. PNU159682 to anti-CD22 antibody (anti-CD22-NMS249) exhibits strong anti-tumor effects in vitro. Anti-CD22-NMS249 (PNU159682 to anti-CD22 antibody) is active in in vitro viability assays of NHL cell lines and is 2 to 20 fold more potent than pinatuzumab vedotin, the ADC anti-CD22-NMS249 is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC₅₀ values of 0.058 nM, 0.030 nM, 0.0221 nM, and 0.01 nM, respectively.
PNU-159682 (100 µM) weakly inhibits topoisomerase II unknotting activity. PNU-159682 shows cytotoxic effect on CAIX-expressing SKRC-52 cells with IC₅₀ of 25 nM.

In Vivo: PNU-159682 (single-dose; i.v.15 µg/kg) is a maximum tolerated dose in murine L1210 leukemia model. PNU-159682 shows an improved antitumor activity in vivo. The antitumor effect of PNU-159682 (increase in life span=29%) is comparable to that afforded by 90 µg/kg MMDX (increase in life=36%).
PNU-159682 (i.v. 4 µg/kg; q7dx3; 40 days) has a therapeutic response in MX-1 human mammary carcinoma mice. What’s more, from day 39, four out of seven mice receiving PNU-159682 exhibits complete tumor regression.
PNU-159682 is more cytotoxic than doxorubicin and can be used to develop a new class of ADCs. PNU159682 to anti-CD22 antibody (anti-CD22-NMS249) exhibits strong anti-tumor effects in vivo. ADC dose (anti-CD22-NMS249; 50 µg/m2 conjugated PNU-159682) is well tolerated in mice and results in less than 10% weight loss.
In the BJAB.Luc model the efficacy of antiCD22-NMS249 (single dose; 2 mg/kg) is similar to anti-CD22-vc-MMAE. At 2 mg/kg dosage, antiCD22-NMS249 gives complete remission of the tumors (NMS249: 110-134%TGI vs. vc-MMAE: 114-143%TGI). Additionally, a single dose of antiCD22-NMS249 at 2 mg/kg results in tumor stasis for three weeks.

相关产品：Natural Product Like Compound Library | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Toxins for Antibody-Drug Conjugate Research Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Anti-Blood Cancer Compound Library | Doxorubicin hydrochloride | Paclitaxel | Etoposide | Mitomycin C | Methotrexate | Irinotecan | SN-38 | Camptothecin | Topotecan Hydrochloride | Epirubicin hydrochloride | Daunorubicin hydrochloride | Exatecan mesylate | Mertansine | Suramin sodium salt | Berberine chloride | Mitoxantrone | Betulinic acid | EIDD-1931 | Idarubicin hydrochloride | Aldoxorubicin | D8-MMAE | Banoxantrone dihydrochloride | Calicheamicin | β-Lapachone | Teniposide

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。